{"id":"cggv:4a7e6901-d478-44c4-bd03-2c344029d4bbv1.1","type":"EvidenceStrengthAssertion","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"cggv:4a7e6901-d478-44c4-bd03-2c344029d4bb_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10008","date":"2017-09-05T16:00:00.000Z","role":"Approver"},{"id":"cggv:4a7e6901-d478-44c4-bd03-2c344029d4bb_publish_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10008","date":"2021-01-08T14:56:53.902Z","role":"Publisher"}],"evidence":[{"id":"cggv:4a7e6901-d478-44c4-bd03-2c344029d4bb_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:4a7e6901-d478-44c4-bd03-2c344029d4bb_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:89b0f0c4-a3ff-4d19-ad08-6dbdeb511bf2","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:dc727aaf-a2ed-44dd-b3e9-3e11022acda8","type":"Finding","demonstrates":{"id":"cg:GeneExpressionB"},"dc:description":"Using 2-DE and Mass spec, they identified 34 differentially expressed proteins with a 2-fold difference between the G203S OE mutant hearts compared to the WT OE hearts.  Most of the protein misregulated are for cytoskeletal (actin), and cytoplasmic and mitochondrial proteins. Several of the Myosin light chains are also upregulated, while the actins are downregulated. They confirmed desmin upregulation that was identified by 2-DE, by subsequent western blot analysis.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/19715700","type":"dc:BibliographicResource","dc:abstract":"Hypertrophic cardiomyopathy (HCM) is a genetic disorder caused by mutations in genes encoding sarcomere proteins. The mechanisms involved in the development of cardiac hypertrophy and heart failure remain poorly understood. Global proteomic profiling was used to study the cardiac proteome of mice predisposed to developing HCM. Hearts from three groups of mice (n=3 hearts per group) were studied: non-transgenic (NTG) and cardiac-specific transgenic models over-expressing either the normal (TnI(WT)) or a mutant cardiac troponin I gene (Gly203Ser; TnI(G203S)). Two-dimensional gel electrophoresis (2-DE) coupled with tandem mass spectrometry was used to identify proteins. Image analysis was performed using Progenesis SameSpots. A total of 34 proteins with at least a twofold change in the TnI(G203S) mouse model were identified. Alterations were detected in components involved in energy production, Ca(2+) handling, and cardiomyocyte structure. Expression level changes in cytoskeletal and contractile proteins were well represented in the study, including the intermediate filament protein desmin, which was further investigated in two additional physiological and pathological settings, i.e., exercise treatment, and severe heart failure in a novel double-mutant TnI-203/MHC-403 model of HCM. This study highlights the potential role of tissue proteomic profiling for mapping proteins, which may be critical in cardiac dysfunction and progression to heart failure in HCM.","dc:creator":"Lam L","dc:date":"2010","dc:title":"Differential protein expression profiling of myocardial tissue in a mouse model of hypertrophic cardiomyopathy."},"rdfs:label":"Lam 2010 Expression"}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"cggv:2f1eeb13-8746-41d6-9d2d-3580901dedd2","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:85600ce3-08d7-4a21-bf6d-73e391242817","type":"Finding","demonstrates":{"id":"obo:MI_0915"},"dc:description":"Y2H luciferase assay shows that the G203S mutation reduces binding of TnI/TNNI3 with TnC and TnT, protein required for association with thin filaments, and Ca2+ sensing.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/16950368","type":"dc:BibliographicResource","dc:abstract":"Gene mutations in cardiac troponin I (cTnI) account for up to 5% of genotyped families with familial hypertrophic cardiomyopathy (FHC). Little is known about how cTnI mutations cause disease. Five lines of transgenic mice were generated which overexpress the human disease-causing cTnI gene mutation, Gly203Ser (designated cTnI-G203S), in a cardiac-specific manner. Mice were compared to transgenic mice that overexpress normal cTnI (cTnI-wt) and non-transgenic littermates (NTG). cTnI-G203S mice developed all the characteristic features of FHC by age 21 weeks. Left ventricular hypertrophy was observed on echocardiography (1.25+/-0.05 mm vs. 0.86+/-0.02 mm in cTnI-wt, P<0.01), associated with a significant 4-fold increase in RNA markers of hypertrophy, ANF and BNP. Myocyte hypertrophy, myofiber disarray and interstitial fibrosis were observed in cTnI-G203S mice. Expression of the cTnI-G203S mutation in neonatal cardiomyocytes resulted in a significant increase in myocyte volume, and reduced interactions with both troponins T and C. Ca2+ cycling was abnormal in adult cardiomyocytes extracted from cTnI-G203S mice, with a prolonged decay constant in Ca2+ transients and a reduced decay constant in response to caffeine treatment. Mice with the cTnI-G203S gene mutation develop all the phenotypic features of human FHC. The cTnI-G203S mutation disrupts interactions with partner proteins, and results in intracellular Ca2+ dysregulation early in life, suggesting a pathogenic role in development of FHC.","dc:creator":"Tsoutsman T","dc:date":"2006","dc:title":"Molecular insights from a novel cardiac troponin I mouse model of familial hypertrophic cardiomyopathy."},"rdfs:label":"Tsoutsman 2006 Protein Interaction"}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5},{"id":"cggv:5d681a03-8308-4518-a51c-df0a4679207c","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:1618cba4-341e-4611-a2e1-9ea71e6b8a77","type":"Finding","demonstrates":{"id":"cg:BiochemicalFunctionB"},"dc:description":"Expression of the rat R146G mutation in rat cardiomyocytes rendered the myocytes more sensitive to Ca2+. The R146G mutant was shown to incorporate into myofilaments. Incorporation of the FLAG-ratR146G mutant into cardiomyocytes was reduced compared to FLAG-WT TnI.  Also show that the analogous mutation in the slow skeletal isoform of TNNI3 (ssTnI or STnI) alters its Ca2+ sensitivity under acidosis.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/12242271","type":"dc:BibliographicResource","dc:abstract":"The heightened Ca2+ sensitivity of force found with hypertrophic cardiomyopathy (HCM)-associated mutant cardiac troponin I (cTnIR145G; R146G in rodents) has been postulated to be an underlying cause of hypertrophic growth and premature sudden death in humans and in animal models of the disease. Expression of slow skeletal TnI (ssTnI), a TnI isoform naturally expressed in developing heart, also increases myofilament Ca2+ sensitivity, yet its expression in transgenic mouse hearts is not associated with overt cardiac disease. Gene transfer of TnI isoforms or mutants into adult cardiac myocytes is used here to ascertain if expression levels or functional differences between HCM TnI and ssTnI could help explain these divergent organ-level effects. Results showed significantly reduced myofilament incorporation of cTnIR146G compared with ssTnI or wild-type cTnI. Despite differences in myofilament incorporation, ssTnI and cTnIR146G expression each resulted in enhanced myofilament tension in response to submaximal Ca2+ under physiological ionic conditions. Myofilament expression of an analogous HCM mutation in ssTnI (ssTnIR115G) did not further increase myofilament Ca2+ sensitivity of tension compared with ssTnI. In contrast, there was a divergent response under acidic pH conditions, a condition associated with the myocardial ischemia that often accompanies hypertrophic cardiomyopathy. The acidic pH-induced decrease in myofilament Ca2+ sensitivity was significantly greater in myocytes expressing cTnIR146G and ssTnIR115G compared with ssTnI. These results suggest that differences in pH sensitivities between wild-type ssTnI and mutant TnI proteins may be one factor in helping explain the divergent organ and organismal outcomes in TnI HCM- and ssTnI-expressing mice.","dc:creator":"Westfall MV","dc:date":"2002","dc:title":"Myofilament calcium sensitivity and cardiac disease: insights from troponin I isoforms and mutants."},"rdfs:label":"Westfall 2002 Biochemical Function"}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"cggv:5099c36f-6c7e-477e-8cb0-69db64274944","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:80628631-7d83-4535-ab20-6ff72bcb00c1","type":"Finding","demonstrates":{"id":"cg:BiochemicalFunctionB"},"dc:description":"The patient derived G203S mutation was expressed in cardiomyocytes by viral infection. Cell volume was significantly increased compared to OE of WT, vector induced or control no-infected cells","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16950368","rdfs:label":"Tsoutsman 2006 Biochemical Function"}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2},{"id":"cggv:4a7e6901-d478-44c4-bd03-2c344029d4bb_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:04240685-c6b1-4301-b719-ccadd7e5c019","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:437cd770-5be3-4c80-a86c-dc6a55e179be","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"By 21 weeks old the G203S mice develop LV hypertrophy, max wall thickness of 1.25mm (in mice), and reduction of LV end diastolic diameter. Interstitial fibrosis and myofiber disarray were evident. ECGs showed prolongation of the PR interval at 30 weeks (consistent with HCM). RNA expression markers of HCM were elevated in the mutant hearts.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16950368","rdfs:label":"Tsoutsman 2006 Mouse Model"}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1,"dc:description":"used the alpha MHC promoter. All transgenic lines developed hallmarks of HCM but at different times, depending on the amount of OE. No arrhythmias observed even after epinephrine challenge."},{"id":"cggv:699e2016-baa6-41b3-a9b8-806a88c53b5b","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:f2b0b533-ed84-4085-9095-8a45d618198d","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"No changes in heart/body weight ratios were observed. No myocyte disarray, or fibrosis was observed, nor changes to ventricular wall thickness. Despite no changes, they did find increased Ca2+ sensitivity in the R145G skinned papillary muscle fibers.  energy cost (ATPase activity) was significantly increased in the R145G mutant fibers compared to WT OE.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/18430738","type":"dc:BibliographicResource","dc:abstract":"In this study, we addressed the functional consequences of the human cardiac troponin I (hcTnI) hypertrophic cardiomyopathy R145G mutation in transgenic mice. Simultaneous measurements of ATPase activity and force in skinned papillary fibers from hcTnI R145G transgenic mice (Tg-R145G) versus hcTnI wild type transgenic mice (Tg-WT) showed a significant decrease in the maximal Ca(2+)-activated force without changes in the maximal ATPase activity and an increase in the Ca(2+) sensitivity of both ATPase and force development. No difference in the cross-bridge turnover rate was observed at the same level of cross-bridge attachment (activation state), showing that changes in Ca(2+) sensitivity were not due to changes in cross-bridge kinetics. Energy cost calculations demonstrated higher energy consumption in Tg-R145G fibers compared with Tg-WT fibers. The addition of 3 mm 2,3-butanedione monoxime at pCa 9.0 showed that there was approximately 2-4% of force generating cross-bridges attached in Tg-R145G fibers compared with less than 1.0% in Tg-WT fibers, suggesting that the mutation impairs the ability of the cardiac troponin complex to fully inhibit cross-bridge attachment under relaxing conditions. Prolonged force and intracellular [Ca(2+)] transients in electrically stimulated intact papillary muscles were observed in Tg-R145G compared with Tg-WT. These results suggest that the phenotype of hypertrophic cardiomyopathy is most likely caused by the compensatory mechanisms in the cardiovascular system that are activated by 1) higher energy cost in the heart resulting from a significant decrease in average force per cross-bridge, 2) slowed relaxation (diastolic dysfunction) caused by prolonged [Ca(2+)] and force transients, and 3) an inability of the cardiac TnI to completely inhibit activation in the absence of Ca(2+) in Tg-R145G mice.","dc:creator":"Wen Y","dc:date":"2008","dc:title":"Functional consequences of the human cardiac troponin I hypertrophic cardiomyopathy mutation R145G in transgenic mice."},"rdfs:label":"Wen 2008 Mouse Model"}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0.5,"dc:description":"potential contradictory evidence, as no changes were observed compared to those seen when the mouse homolog of the R146G was OE. This could be because the levels of expression differ, as well as how the human isoform may interact in the mouse system. Mutation does not effect turnover rate of the cross-bridge"},{"id":"cggv:8d202bf6-b9d2-4cb9-94d3-11e544fb8ade","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:dd353272-c805-47d7-9397-4d8bf1f13439","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"OE of R146G in rabbits in two lines (52 and 71 that expressed >50%) resulted in death at 1 week old due to heart failure. Major sarcomere disruption and contractures were observed. Line 51 with ~28% expression of WT, was not lethal, and showed expression specifically in the ventricles only. By 18months significant fibrosis and myocyte disarray were observed.  slight thickening in the left ventricular wall thickness and increased septal thickens were observed. Both the line 51 and line 52 show calcium sensitivity, with the line 52 having more modest effects due to reduced expression compared to line 51. Increases in Cx43 and phospho-Cx43 in the mutant cardiomyocytes, possible link to arrhythmias.  While no gross ECG abnormalities were detected, the QTmax interval was significantly higher in the R146G mutant rabbits, an attribute of HCM.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/15867176","type":"dc:BibliographicResource","dc:abstract":"Transgenic and gene-targeted models have focused on the mouse. Fundamental differences between the mouse and human exist in Ca2+ handling during contraction/relaxation and in alterations in Ca2+ flux during heart failure, with the rabbit more accurately reflecting the human system.","dc:creator":"Sanbe A","dc:date":"2005","dc:title":"Transgenic rabbit model for human troponin I-based hypertrophic cardiomyopathy."},"rdfs:label":"Sanbe 2005 Rabbit Model"}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1,"dc:description":"N-terminal FLAG tag added, according to Gomes and Potter 2004, this tag should not alter TNNI3 function, as a c-term tag may due to binding sites for TnC within the c-term. Used the rabbit beta-MHC promoter to direct ventricle specific expression of the mutant transgenes. no increase in mortality in the line 52 modest OE. No changes to ECG found."},{"id":"cggv:f829ad69-a4ad-48a3-a5c4-d3c7e6caac9f","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:1c9d9803-bc0e-4040-b842-7adc475e27b9","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"Overexpression of this line led to the development of HCM, and depending on the dosage, accelerated HCM. Cardiomyocyte morphology was abnormal compared to control mice OE WT TNNI3. Heart function was also impaired, contractility was enhanced and relaxation was impaired. Dose-dependent death effect, was observed in the highest expressing line (line 133) at 17 days old. In a 1.2 fold expressing line (line 121) only developed outward HCM in parous females. But all mutant mice showed abnormal +dP/dt and -dP/dt.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/11055985","type":"dc:BibliographicResource","dc:abstract":"Multiple mutations in cardiac troponin I (cTnI) have been associated with familial hypertrophic cardiomyopathy. Two mutations are located in the cTnI inhibitory domain, a highly negatively charged region that alternately binds to either actin or troponin C, depending on the intracellular concentration of calcium. This region is critical to the inhibition of actin-myosin crossbridge formation when intracellular calcium is low. We modeled one of the inhibitory domain mutations, arginine145-->glycine (TnI(146Gly) in the mouse sequence), by cardiac-specific expression of the mutated protein in transgenic mice. Multiple lines were generated with varying degrees of expression to establish a dose relationship; the severity of phenotype could be correlated directly with transgene expression levels. Transgenic mice overexpressing wild-type cTnI were generated as controls and analyzed in parallel with the TnI(146Gly) animals. The control mice showed no abnormalities, indicating that the phenotype of TnI(146Gly) was not simply an artifact of transgenesis. In contrast, TnI(146Gly) mice showed cardiomyocyte disarray and interstitial fibrosis and suffered premature death. The functional alterations that seem to be responsible for the development of cardiac disease include increased skinned fiber sensitivity to calcium and, at the whole organ level, hypercontractility with diastolic dysfunction. Severely affected lines develop a pathology similar to human familial hypertrophic cardiomyopathy but within a dramatically shortened time frame. These data establish the causality of this mutation for cardiac disease, provide an animal model for understanding the resultant pathogenic structure-function relationships, and highlight the differences in phenotype severity of the troponin mutations between human and mouse hearts.","dc:creator":"James J","dc:date":"2000","dc:title":"Transgenic modeling of a cardiac troponin I mutation linked to familial hypertrophic cardiomyopathy."},"rdfs:label":"James 2000 Mouse Model"}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1,"dc:description":"The inhibitory domain of TNNI3 is an highly conserved 11AA acid sequence. The R145G mutation is within the inhibitory domain. ClinVar info: NM_000363.4(TNNI3):c.433C>G (p.Arg145Gly), variant id: 1241.  While there is no frequency data on this specific mutation two other missense mutations at this site R145Q and R145Y have frequencies of 0.00002490 and 0.000008299, respectively; did not show increases in ventricular weight compared to body, but rather increased atrial weight compared to body."},{"id":"cggv:15d2f866-8b66-4aa6-98e1-8e10efd999ca","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:71bfe9cb-90e9-499d-af87-71195adceff2","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"The neo+/+ (homozygous for the R21C mutation and carrying two copies of the neomycin cassette) died between P18-20, similar to other cTnI mutant mice, but the hearts appeared morphologically normal though [Interestingly, mRNA and Western blot showed loss of cTnI expression in the heart (data not shown)]. The R21C homozygous mice with the neo cassette removed were viable, fertile, and lived to at least 18 months. HCM phenotypes arose in the R21C mutant mice when aged greater than 12 months. The R21C mutant allele was not phosphorylated in a PKA dependent manner, which would affect it's function and ability to dimerize with other troponin proteins. After 12 months of age, the homozygous R21C mutant mice showed significant increases in the heart/body weight ratio, and increases in the RNA expression of conserved markers of HCM.  Both the homozygous and heterozygous R21C mice showed increase in the RNA expression of atrial natriuretic peptide, brain natriuretic peptide, and beta-MHC. Left ventricular outer septal wall thickness was increased in the R21C mutants compared to WT, and there was noticeable interstitial fibrosis.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/22086914","type":"dc:BibliographicResource","dc:abstract":"The R21C substitution in cardiac troponin I (cTnI) is the only identified mutation within its unique N-terminal extension that is associated with hypertrophic cardiomyopathy (HCM) in man. Particularly, this mutation is located in the consensus sequence for Î²-adrenergic-activated protein kinase A (PKA)-mediated phosphorylation. The mechanisms by which this mutation leads to heart disease are still unclear. Therefore, we generated cTnI knock-in mouse models carrying an R21C mutation to evaluate the resultant functional consequences. Measuring the in vivo levels of incorporated mutant and WT cTnI, and their basal phosphorylation levels by top-down mass spectrometry demonstrated: 1) a dominant-negative effect such that, the R21C+/- hearts incorporated 24.9% of the mutant cTnI within the myofilament; and 2) the R21C mutation abolished the in vivo phosphorylation of Ser(23)/Ser(24) in the mutant cTnI. Adult heterozygous (R21C+/-) and homozygous (R21C+/+) mutant mice activated the fetal gene program and developed a remarkable degree of cardiac hypertrophy and fibrosis. Investigation of cardiac skinned fibers isolated from WT and heterozygous mice revealed that the WT cTnI was completely phosphorylated at Ser(23)/Ser(24) unless the mice were pre-treated with propranolol. After propranolol treatment (-PKA), the pCa-tension relationships of all three mice (i.e. WT, R21C+/-, and R21C+/+) were essentially the same. However, after treatment with propranolol and PKA, the R21C cTnI mutation reduced (R21C+/-) or abolished (R21C+/+) the well known decrease in the Ca(2+) sensitivity of tension that accompanies Ser(23)/Ser(24) cTnI phosphorylation. Altogether, the combined effects of the R21C mutation appear to contribute toward the development of HCM and suggest that another physiological role for the phosphorylation of Ser(23)/Ser(24) in cTnI is to prevent cardiac hypertrophy.","dc:creator":"Wang Y","dc:date":"2012","dc:title":"Generation and functional characterization of knock-in mice harboring the cardiac troponin I-R21C mutation associated with hypertrophic cardiomyopathy."},"rdfs:label":"Wang 2012 Mouse Model"}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1,"dc:description":"Per ClinVar: https://www.ncbi.nlm.nih.gov/ClinVar/variation/12434/#supporting-observations. In a proband who was found to have apical hypertrophy (CMH7; 613690) after presenting with atrial fibrillation, Arad et al. (2005) identified a heterozygous arg21-to-cys (R21C) mutation in the TNNI3 gene. The proband's father, 3 sibs, and her 18-year-old daughter all had sudden cardiac death. Clinical evaluation of 3 other mutation carriers in the family revealed that 1 had asymmetric septal hypertrophy, another had isolated left atrial enlargement, and the third had normal cardiac dimensions despite an abnormal electrocardiogram. Arad et al. (2005) stated that they also identified the R21C mutation in another CMH family, in which 4 patients had subaortic asymmetric hypertrophy and 1 mutation carrier with normal cardiac dimensions was resuscitated from sudden cardiac death."}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6},{"id":"cggv:4a7e6901-d478-44c4-bd03-2c344029d4bb_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:4a7e6901-d478-44c4-bd03-2c344029d4bb_cc_el","type":"EvidenceLine","evidence":[{"id":"cggv:cced6a9c-6821-48d0-8340-cb91c9eb4076","type":"EvidenceLine","evidence":[{"id":"cggv:cced6a9c-6821-48d0-8340-cb91c9eb4076_cc_evidence_item","type":"Finding","caseCohort":{"id":"cggv:a69be638-0eba-48dc-b7d4-4e00138c75ad","type":"Cohort","allGenotypedSequenced":0,"detectionMethod":"MAF threshold of 1x10-4. For each gene of rare variants in ExAC was calculated by dividing sum of adjusted allele count by the mean of total adjusted alleles. For HCM cohort, it was calculated by dividing the sum of rare variants identified in cases by total number of patients analyzed.","evidence":[{"id":"cggv:cced6a9c-6821-48d0-8340-cb91c9eb4076_cc_evidence_item"}],"numWithVariant":0,"relatedCondition":{"id":"obo:MONDO_0005045"}},"controlCohort":{"id":"cggv:856297b9-f374-4539-b7cd-5d01e3e1a284","type":"Cohort","allGenotypedSequenced":0,"detectionMethod":"MAF threshold of 1x10-4. For each gene of rare variants in ExAC was calculated by dividing sum of adjusted allele count by the mean of total adjusted alleles. For HCM cohort, it was calculated by dividing the sum of rare variants identified in cases by total number of patients analyzed.","evidence":[{"id":"cggv:cced6a9c-6821-48d0-8340-cb91c9eb4076_cc_evidence_item"}],"numWithVariant":0},"method":{"id":"cg:SingleVariantAnalysis"},"statisticalSignificanceType":"","statisticalSignificanceValueType":"","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/27532257","type":"dc:BibliographicResource","dc:abstract":"The accurate interpretation of variation in Mendelian disease genes has lagged behind data generation as sequencing has become increasingly accessible. Ongoing large sequencing efforts present huge interpretive challenges, but they also provide an invaluable opportunity to characterize the spectrum and importance of rare variation.","dc:creator":"Walsh R","dc:date":"2017","dc:title":"Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples."},"rdfs:label":"Walsh 2016 Case-control"}],"specifiedBy":"GeneValidityCaseControlSingleVariantAnalysisCriteria","strengthScore":2,"dc:description":"Case excess defined by subtracting the proportion of individuals in ExAC with a filtered variant from the proportion in the clinical cohort. Nontruncating case excess: 0.01947, OR 11.6 (8.93-15), EF 0.91 (0.89-0.93). Truncating case excess: 0.00057, OR 2.43 (0.99-6), EF 0.59 (0-0.84)."}],"specifiedBy":"GeneValidityOverallCaseControlEvidenceCriteria","strengthScore":2},{"id":"cggv:4a7e6901-d478-44c4-bd03-2c344029d4bb_seg_el","type":"EvidenceLine","specifiedBy":"GeneValiditySegregationEvidencCriteria","strengthScore":1.5},{"id":"cggv:4a7e6901-d478-44c4-bd03-2c344029d4bb_ad_other_el","type":"EvidenceLine","evidence":[{"id":"cggv:b884f075-10b2-48cd-99a7-a28bb47f92d4_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:8fa25b99-f4d0-49e6-ad04-f646266ee63c","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":30,"phenotypeFreeText":"ACM, 21mm","sex":"Female","variant":{"id":"cggv:b884f075-10b2-48cd-99a7-a28bb47f92d4_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:9681cc35-5cb4-4ba6-878e-35cf52292a83","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000363.5(TNNI3):c.433C>T (p.Arg145Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA021667"}},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/15607392","type":"dc:BibliographicResource","dc:abstract":"The aim of this study was to evaluate the potential utility of genetic diagnosis in clinical management of families with hypertrophic cardiomyopathy (HCM) caused by mutations in the gene for cardiac troponin I (TNNI3).","dc:creator":"Mogensen J","dc:date":"2004","dc:title":"Frequency and clinical expression of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/15607392","rdfs:label":"Mogensen 2004 Family H215 Proband"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.25,"dc:description":"gnomAD: Max Freq (South Asian): 6.057e-05. Overall: 8.299e-06; founder variant"},{"id":"cggv:a8ecfcb3-364a-4f4e-911f-dd8b9bcc73aa_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:1070925e-583d-4094-bdaa-77af7ff5430a","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":27,"phenotypeFreeText":"LVEF of 50%, IVSd normal, entire apical wall 18mm, LA dimension 48mm, paroxysmal AF","sex":"Male","variant":{"id":"cggv:a8ecfcb3-364a-4f4e-911f-dd8b9bcc73aa_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:7a39c3ac-c7de-4294-a5b0-cac56c923a65","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000363.5(TNNI3):c.433C>G (p.Arg145Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA021660"}},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/20641121","type":"dc:BibliographicResource","dc:abstract":"We sought to describe the long-term outcome of individuals in 4 Korean families with hypertrophic cardiomyopathy (HCM) with known mutations.","dc:creator":"Choi JO","dc:date":"2010","dc:title":"Long-term outcome of 4 Korean families with hypertrophic cardiomyopathy caused by 4 different mutations."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/20641121","rdfs:label":"Choi 2010 Family 3 Proband"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.5,"dc:description":"Variant absent from gnomAD; OMIM: In affected members of a large multigenerational Korean family with hypertrophic cardiomyopathy-7 (CMH7; 613690), Kimura et al. (1997) identified a CGG-to-CAG nucleotide change in the TNNI3 gene, resulting in an arg145-to-gly (R145G) substitution at a conserved residue. Lang et al. (2002) showed that the R145G mutation impairs force development and relaxation. These intrinsic contractile changes would likely result in diastolic dysfunction in vivo. Hypertrophy could arise as a compensatory mechanism.\nWen et al. (2008) found that skinned papillary fibers from transgenic mice expressing human cTnI with the R145G mutation (Tg-R145G mice) developed significantly decreased maximal Ca(2+)-activated force without changes in maximal ATPase activity compared with transgenic mice expressing wildtype human cTnI (Tg-WT mice). Tg-R145G fibers showed increased Ca(2+) sensitivity in both ATPase and force development compared with Tg-WT fibers. Energy cost calculations demonstrated higher energy consumption in Tg-R145G fibers compared with Tg-WT fibers. Use of a myosin ATPase inhibitor showed that R145G impaired the ability of the cardiac troponin complex to fully inhibit cross-bridge attachment under relaxing conditions. Furthermore, electrical stimulation caused prolonged force and intracellular Ca(2+) concentration transients in intact Tg-R145G papillary muscles compared with Tg-WT papillary muscles. Wen et al. (2008) concluded that hypertrophic cardiomyopathy due to the R145G mutation is likely caused by compensatory changes activated by higher energy cost of cross-bridge formation, slowed rate of fiber relaxation, and the inability of cardiac fibers to completely relax in the absence of Ca(2+)."},{"id":"cggv:f4e5b390-4721-434e-b10d-948900444871_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:263edf87-2507-4813-9486-d9ac2e61f79b","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":48,"detectionMethod":"not given","phenotypeFreeText":"LVOT=18mm, MWT=14mm","phenotypes":"obo:HP_0001639","previousTesting":true,"previousTestingDescription":"Negative for MYH7, MYBPC3 TNNT2, MYL2, MYL3, TPM1, ACTC.","sex":"Male","variant":{"id":"cggv:f4e5b390-4721-434e-b10d-948900444871_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:45a48889-092a-495c-ba29-df380ec57b47","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000363.5(TNNI3):c.370G>C (p.Glu124Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA021554"}},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/25086479","type":"dc:BibliographicResource","dc:abstract":"Hypertrophic cardiomyopathy (HCM) is a common genetic cardiac disorder associated with sudden death, heart failure, and stroke. The aim of the present study was to evaluate the prevalence and types of mutations in symptomatic patients with HCM in Taiwan.","dc:creator":"Chiou KR","dc:date":"2015","dc:title":"Detection of mutations in symptomatic patients with hypertrophic cardiomyopathy in Taiwan."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/25086479","rdfs:label":"Chiou 2015 Case H-21"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.1,"dc:description":"gnomAD: Max Freq: 0.0001165 (East Asian). Overall: 8.442e-06; Taiwanese HCM cohort. Absent from 200 unrelated control chromosomes; GeneDx: The E124Q variant in the TNNI3 gene was identified in one proband and two of his affected relatives in a study of 38 Taiwanese probands diagnosed with HCM (Chiou et al., 2014). E124Q was not observed in approximately 6,300 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The E124Q variant is a semi-conservative amino acid substitution, which may impact secondary protein structure as these residues differ in some properties. This substitution occurs at a position where amino acids with similar properties to Glutamic acid are tolerated across species. Nevertheless, in silico analysis predicts this variant is probably damaging to the protein structure/function. Therefore, based on the currently available information, it is unclear whether this variant is pathogenic or rare benign."},{"id":"cggv:6f03b0c9-2753-4b80-bfb8-d17e7082d53b_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:865b2edc-20d5-4ee3-aa0d-ead0a37164df","type":"Proband","detectionMethod":"not provided","phenotypeFreeText":"All 3 affected members with WCW.","phenotypes":["obo:HP_0001714","obo:HP_0001716"],"previousTesting":true,"previousTestingDescription":"No mutations in 6 known HCM genes.","sex":"Female","variant":{"id":"cggv:6f03b0c9-2753-4b80-bfb8-d17e7082d53b_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:8c73dca0-865a-4ce2-96e5-7bc2ab05d484","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000363.5(TNNI3):c.607G>A (p.Gly203Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA022043"}},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/9241277","type":"dc:BibliographicResource","dc:abstract":"Hypertrophic cardiomyopathy (HCM), the most common cause of sudden death in the young, is an autosomal dominant disease characterized by ventricular hypertrophy accompanied by myofibrillar disarrays. Linkage studies and candidate-gene approaches have demonstrated that about half of the patients have mutations in one of six disease genes: cardiac beta-myosin heavy chain (c beta MHC), cardiac troponin T (cTnT), alpha-tropomyosin (alpha TM), cardiac myosin binding protein C (cMBPC), ventricular myosin essential light chain (vMLC1) and ventricular myosin regulatory light chain (vMLC2) genes. Other disease genes remain unknown. Because all the known disease genes encode major contractile elements in cardiac muscle, we have systematically characterized the cardiac sarcomere genes, including cardiac troponin I (cTnI), cardiac actin (cACT) and cardiac troponin C (cTnC) in 184 unrelated patients with HCM and found mutations in the cTnI gene in several patients. Family studies showed that an Arg145Gly mutation was linked to HCM and a Lys206Gln mutation had occurred de novo, thus strongly suggesting that cTnI is the seventh HCM gene.","dc:creator":"Kimura A","dc:date":"1997","dc:title":"Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/9241277","rdfs:label":"Family J859 Proband"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0,"dc:description":"Variant absent from gnomAD; 184 probands with HCM (148 HCM, 36 AHCM) patient cohort. Not found in over 500 control chromosomes; No points since the variant is segregating with WCW."},{"id":"cggv:a990cdb8-6b10-4248-b616-93aac73ee5d3_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:61952d73-f96a-4f4a-8a1c-554b4986088f","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":74,"phenotypeFreeText":"Dyspnoea, SR, LVH, T-wave inversion, LVWT 24mm, LVOTO","sex":"Female","variant":{"id":"cggv:a990cdb8-6b10-4248-b616-93aac73ee5d3_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:a6bec8b7-4196-4c7b-8691-ce1fb588c584","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000363.5(TNNI3):c.485G>A (p.Arg162Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA021744"}},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/15698845","type":"dc:BibliographicResource","dc:abstract":"Hypertrophic cardiomyopathy (HCM) is an autosomal dominant disorder caused by mutations in sarcomeric proteins. Cardiac troponin I (cTnI) is a key switch molecule in the sarcomere. Mutations in cTnI have been identified in <1% of genotyped HCM families.","dc:creator":"Doolan A","dc:date":"2005","dc:title":"Cardiac troponin I mutations in Australian families with hypertrophic cardiomyopathy: clinical, genetic and functional consequences."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/15698845","rdfs:label":"II:4"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":1,"dc:description":"gnomAD: gnomAD: South Asian (6.497e-5), Overall (4.070e-5); GeneDx: The R162Q pathogenic variant in the TNNI3 gene has been reported in multiple unrelated patients with HCM (Van Driest et al., 2003; Mogensen et al., 2004; Doolan et al., 2005; Ingles et al., 2005; Rani et al., 2012; Coppini et al., 2014; Kapplinger et al., 2014; Mouton et al., 2015) and affects the Arginine 162 residue located within a functionally significant troponin C binding site domain. Van Driest et al. (2003) initially reported the R162Q variant in two unrelated individuals with HCM, and did not detect it in 400 control chromosomes. In addition, in vitro functional studies using HEK293 cells showed that the R162Q variant results in a 50% reduction of the troponin I and troponin C interaction (Doolan et al., 2005). Furthermore, pathogenic variants in the same residue (R162P, R162W) have been reported in association with HCM (Stenson et al., 2014), supporting the functional importance of this residue. In addition, R162Q was not observed in approximately 6,100 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. In summary, R162Q in the TNNI3 gene is interpreted as a pathogenic variant."},{"id":"cggv:06da8163-022c-47f7-b9bd-e43e3a498702_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:61c87c6c-fd3f-4caf-9998-b11f8b833a6f","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":37,"detectionMethod":"120 families evaluated for mutations in TNNI3. PCR and sequencing.","phenotypeFreeText":"ECG: SR, LVH, dilated atria, ST changes, LVWT 17mm","sex":"Male","variant":{"id":"cggv:06da8163-022c-47f7-b9bd-e43e3a498702_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:2b94790a-b744-4912-9bec-60a4a01bd5a4","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000363.5(TNNI3):c.611G>A (p.Arg204His)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA022060"}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/15698845"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/15698845","rdfs:label":"II:1"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.5,"dc:description":"Variant absent from gnomAD; Y2H: significant reduction in interaction with cTnC and CTnT."},{"id":"cggv:8c0b3489-74ad-4568-8032-acbd65e4ca91_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:38a1271f-eba8-45cc-bded-1c1218101945","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":28,"detectionMethod":"Sequenced all exons of TNNI3 in 101 HCM patients and 160 controls from southern India.","phenotypeFreeText":"Severe HOCM with IVS thickness of 25mm; Family history of sudden death. 5 yo unaffected son with variant.","sex":"Male","variant":{"id":"cggv:8c0b3489-74ad-4568-8032-acbd65e4ca91_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:71e264f5-b513-4dfe-9c3e-ac4b2ffd2887","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000363.5(TNNI3):c.293G>A (p.Arg98Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA051127"}},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/22876777","type":"dc:BibliographicResource","dc:abstract":"Troponin I (TNNI3) is the inhibitory subunit of the thin filament regulatory complex Troponin, which confers calcium-sensitivity to striated muscle actomyosin ATPase activity. Mutations (2-7%) in this gene had been reported in hypertrophic cardiomyopathy patients (HCM). However, the frequencies of mutations and associated clinical presentation have not been established in cardiomyopathy patients of Indian origin, hence we have undertaken this study.","dc:creator":"Rani DS","dc:date":"2012","dc:title":"High prevalence of Arginine to Glutamine substitution at 98, 141 and 162 positions in Troponin I (TNNI3) associated with hypertrophic cardiomyopathy among Indians."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/22876777","rdfs:label":"Rani 2012 Family"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.1,"dc:description":"gnomAD: Max Freq: 1.509e-05 (European, Non-Finnish). Overall: 8.352e-06."},{"id":"cggv:1ea98692-9d83-49ff-8ccb-645751db65f7_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:b4a670cd-04cd-48b0-ae5e-69e5ed824472","type":"Proband","phenotypeFreeText":"Developed severe biventricular hypertropy with bilateral dilation over 12 year period. Died from heart failure at 40 years.","sex":"Female","variant":{"id":"cggv:1ea98692-9d83-49ff-8ccb-645751db65f7_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:9681cc35-5cb4-4ba6-878e-35cf52292a83"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/15607392"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/15607392","rdfs:label":"Family H816 Proband"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.25,"dc:description":"gnomAD: Max Freq (South Asian): 6.057e-05. Overall: 8.299e-06; founder variant"},{"id":"cggv:2e659370-11a8-400e-807a-e67eaaef7ad7_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:538fe355-4cae-41a3-8783-edeca0099b17","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":49,"phenotypeFreeText":"Severe hypertrophy (30mm), midcavity LV obstruction.","sex":"Male","variant":{"id":"cggv:2e659370-11a8-400e-807a-e67eaaef7ad7_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:9681cc35-5cb4-4ba6-878e-35cf52292a83"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/15607392"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/15607392","rdfs:label":"Family H805 Proband"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.25,"dc:description":"gnomAD: Max Freq (South Asian): 6.057e-05. Overall: 8.299e-06; founder variant"},{"id":"cggv:ca5ea470-5295-4232-8d10-e2139fa6d5c6_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:13cfdff3-f52a-46e8-badd-d98ebe68a478","type":"Proband","phenotypeFreeText":"HCM","sex":"Female","variant":{"id":"cggv:ca5ea470-5295-4232-8d10-e2139fa6d5c6_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:7f7751c4-4713-4b7e-9bd3-218e55ee0f32","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000363.5(TNNI3):c.596G>A (p.Ser199Asn)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA022024"}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/15607392"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/15607392","rdfs:label":"Family H375 Proband"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.5,"dc:description":"Variant absent from gnomAD; GeneDx: The S199N variant has been reported in multiple individuals with a diagnosis of HCM and was absent in at least 350 control chromosomes (Mogensen et al., 2004; Brito et al. 2005; Andersen et al. 2009; Brito et al., 2012). Mogensen et al. (2004) reported S199N in two unrelated families and this variant was found to segregate with disease in six family members, including two obligate carriers. The S199N variant was not observed in approximately 6100 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. Additionally, the S199 residue was shown to be hyperphosphorylated in a canine heart failure model, and variants in the same residue (S199G) and in nearby residues (A197G, L198V, L198P, M201T, E202G, G203S, G203R) have been reported in HGMD in association with HCM (Zhang et al., 2012; Stenson et al., 2014), further supporting the functional importance of this residue and this region of the protein. Moreover, this substitution occurs at a position that is conserved across species, and in silico analysis predicts this variant is probably damaging to the protein structure/function. Nevertheless, S199N is a conservative amino acid substitution, which is not likely to impact secondary protein structure as these residues share similar properties. Therefore, this variant is likely pathogenic; however, the possibility that it is benign cannot be excluded."},{"id":"cggv:35627033-225f-4d76-84c5-0a35624a014a_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:6c263942-63bf-4a0d-9ee5-a9452712935b","type":"Proband","detectionMethod":"not provided","phenotypeFreeText":"Apical HCM.","previousTesting":true,"previousTestingDescription":"No mutations in 6 known HCM genes.","sex":"Male","variant":{"id":"cggv:35627033-225f-4d76-84c5-0a35624a014a_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:3f16b487-9b2e-443f-961e-308afc512de9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"TNNI3, 3-BP DEL, LYS183","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/12433"}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/9241277"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/9241277","rdfs:label":"Family J56 Proband"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.1,"dc:description":"Variant absent from gnomAD; 184 probands with HCM (148 HCM, 36 AHCM) patient cohort. Not found in over 500 control chromosomes."},{"id":"cggv:b28f69f6-c679-4ba5-8c0c-a9688db7cc7f_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:a4161c2e-376d-4c54-9ea1-e0cfc7110e05","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":60,"detectionMethod":"Sequenced all exons of TNNI3 in 101 HCM patients and 160 controls from southern India.","phenotypeFreeText":"Severe asymmetric septal hypertrophy (ASH)with mean thickness of 29mm, abnoromal ECG.","sex":"Male","variant":{"id":"cggv:b28f69f6-c679-4ba5-8c0c-a9688db7cc7f_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:a6bec8b7-4196-4c7b-8691-ce1fb588c584"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/22876777"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/22876777","rdfs:label":"Rani 2012 Family 2 Proband"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":1,"dc:description":"gnomAD: Max Freq: 6.05e-05 (South Asian). Overall: 2.498e-05; GeneDx: The R162Q pathogenic variant in the TNNI3 gene has been reported in multiple unrelated patients with HCM (Van Driest et al., 2003; Mogensen et al., 2004; Doolan et al., 2005; Ingles et al., 2005; Rani et al., 2012; Coppini et al., 2014; Kapplinger et al., 2014; Mouton et al., 2015) and affects the Arginine 162 residue located within a functionally significant troponin C binding site domain. Van Driest et al. (2003) initially reported the R162Q variant in two unrelated individuals with HCM, and did not detect it in 400 control chromosomes. In addition, in vitro functional studies using HEK293 cells showed that the R162Q variant results in a 50% reduction of the troponin I and troponin C interaction (Doolan et al., 2005). Furthermore, pathogenic variants in the same residue (R162P, R162W) have been reported in association with HCM (Stenson et al., 2014), supporting the functional importance of this residue. In addition, R162Q was not observed in approximately 6,100 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. In summary, R162Q in the TNNI3 gene is interpreted as a pathogenic variant."},{"id":"cggv:c8ed4da0-1102-46c9-b506-216b1abfec05_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:cbed464b-1f23-4903-9142-ef0fef89ccc5","type":"Proband","phenotypeFreeText":"HCM, sudden cardiac death at 13 years","sex":"Male","variant":{"id":"cggv:c8ed4da0-1102-46c9-b506-216b1abfec05_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:a6bec8b7-4196-4c7b-8691-ce1fb588c584"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/15607392"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/15607392","rdfs:label":"Family H15 Proband"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":1,"dc:description":"gnomAD: Max Freq: 6.05e-05 (South Asian). Overall: 2.498e-05."},{"id":"cggv:1ce22170-29d6-451e-9aa4-ab6ac4baf1ce_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:107ebb06-71d9-41e0-be03-e36a892702dd","type":"Proband","detectionMethod":"PCR-DCP analysis","phenotypes":"obo:HP_0001714","previousTesting":true,"previousTestingDescription":"No mutations in 6 known HCM genes.","sex":"Male","variant":{"id":"cggv:1ce22170-29d6-451e-9aa4-ab6ac4baf1ce_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:7a39c3ac-c7de-4294-a5b0-cac56c923a65"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/9241277"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/9241277","rdfs:label":"Family K106 Proband"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.5,"dc:description":"Variant absent from gnomAD; 184 probands with HCM (148 HCM, 36 AHCM) patient cohort. Variant Not found in over 500 control chromosomes. OMIM: In affected members of a large multigenerational Korean family with hypertrophic cardiomyopathy-7 (CMH7; 613690), Kimura et al. (1997) identified a CGG-to-CAG nucleotide change in the TNNI3 gene, resulting in an arg145-to-gly (R145G) substitution at a conserved residue. Lang et al. (2002) showed that the R145G mutation impairs force development and relaxation. These intrinsic contractile changes would likely result in diastolic dysfunction in vivo. Hypertrophy could arise as a compensatory mechanism.\nWen et al. (2008) found that skinned papillary fibers from transgenic mice expressing human cTnI with the R145G mutation (Tg-R145G mice) developed significantly decreased maximal Ca(2+)-activated force without changes in maximal ATPase activity compared with transgenic mice expressing wildtype human cTnI (Tg-WT mice). Tg-R145G fibers showed increased Ca(2+) sensitivity in both ATPase and force development compared with Tg-WT fibers. Energy cost calculations demonstrated higher energy consumption in Tg-R145G fibers compared with Tg-WT fibers. Use of a myosin ATPase inhibitor showed that R145G impaired the ability of the cardiac troponin complex to fully inhibit cross-bridge attachment under relaxing conditions. Furthermore, electrical stimulation caused prolonged force and intracellular Ca(2+) concentration transients in intact Tg-R145G papillary muscles compared with Tg-WT papillary muscles. Wen et al. (2008) concluded that hypertrophic cardiomyopathy due to the R145G mutation is likely caused by compensatory changes activated by higher energy cost of cross-bridge formation, slowed rate of fiber relaxation, and the inability of cardiac fibers to completely relax in the absence of Ca(2+)."},{"id":"cggv:684c6038-694e-41e2-b67d-ee69a19700e2_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:f9dbbfc0-1bcd-4309-9b81-99dae6fe8d20","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":25,"sex":"Female","variant":{"id":"cggv:684c6038-694e-41e2-b67d-ee69a19700e2_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:f56a7856-4c50-4d36-8e49-0741fd0d48b6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000363.5(TNNI3):c.485G>C (p.Arg162Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA021749"}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/15698845"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/15698845","rdfs:label":"III:1"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":1,"dc:description":"Variant absent from gnomAD; LMM: The p.Arg162Pro variant in TNNI3 has been reported in at least 5 individuals with HCM and segregated with disease in 3 affected relatives from 1 family (Richard 2005, Doolan 2005, Ingles 2005, Keller 2009, Coppini 2014, LMM unpublished data). It was absent from large population studies (dbSNP rs397516354). In vitro functional studies provide some evidence that this variant may impact protein function (Doolan 2005). However, these types of assays may not accurately represent biological function. In addition, a different disease causing amino acid change at this position (p.Arg162Gln) has been reported, suggesting that a change to this position may not be tolerated. In summary, although additional studies are required to fully establish its clinical significance, the p.Arg162Pro variant is likely pathogenic."},{"id":"cggv:351d8cf2-bc8c-4579-8ad5-08dc685e8728_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:9ee43b35-67d4-4670-a065-88ab9fd5ead8","type":"Proband","phenotypeFreeText":"Septal hypertrophy.","sex":"UnknownEthnicity","variant":{"id":"cggv:351d8cf2-bc8c-4579-8ad5-08dc685e8728_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:9681cc35-5cb4-4ba6-878e-35cf52292a83"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/19035361","type":"dc:BibliographicResource","dc:abstract":"The American Heart Association (AHA) recommends family screening for hypertrophic cardiomyopathy (HCM). We assessed the outcome of family screening combining clinical evaluation and screening for sarcomere gene mutations in a cohort of 90 Danish HCM patients and their close relatives, in all 451 persons. Index patients were screened for mutations in all coding regions of 10 sarcomere genes (MYH7, MYL3, MYBPC3, TNNI3, TNNT2, TPM1, ACTC, CSRP3, TCAP, and TNNC1) and five exons of TTN. Relatives were screened for presence of minor or major diagnostic criteria for HCM and tracking of DNA variants was performed. In total, 297 adult relatives (>18 years) (51.2%) fulfilled one or more criteria for HCM. A total of 38 HCM-causing mutations were detected in 32 index patients. Six patients carried two disease-associated mutations. Twenty-two mutations have only been identified in the present cohort. The genetic diagnostic yield was almost twice as high in familial HCM (53%) vs. HCM of sporadic or unclear inheritance (19%). The yield was highest in families with an additional history of HCM-related clinical events. In relatives, 29.9% of mutation carriers did not fulfil any clinical diagnostic criterion, and in 37.5% of relatives without a mutation, one or more criteria was fulfilled. A total of 60% of family members had no mutation and could be reassured and further follow-up ceased. Genetic diagnosis may be established in approximately 40% of families with the highest yield in familial HCM with clinical events. Mutation-screening was superior to clinical investigation in identification of individuals not at increased risk, where follow-up is redundant, but should be offered in all families with relatives at risk for developing HCM.","dc:creator":"Andersen PS","dc:date":"2009","dc:title":"Diagnostic yield, interpretation, and clinical utility of mutation screening of sarcomere encoding genes in Danish hypertrophic cardiomyopathy patients and relatives."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/19035361","rdfs:label":"Case ZT"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.5,"dc:description":"gnomAD: Max Freq (South Asian): 6.057e-05. Overall: 8.299e-06; GeneDx: The R145W mutation in the TNNI3 gene has been reported multiple times in association with HCM as well as restrictive cardiomyopathy (Mogensen J et al. 2003 and 2004; Van den Wigngaard A et al. 2011) and in multiple unrelated individuals tested for HCM. Van den Wijngaard et al. noted R145W is a founder mutation in the Dutch population and there is variable clinical expression in R145W carriers. Multiple functional studies have noted R145W is located in the region of the gene that is required for inhibition of human cardiac troponin I actomyosin ATPase activity and R145W showed a large increase in Ca2+ sensitivity of both force development, ATPase activity, and other functional impairments (Gomes A et al. 2005; Wen Y et al. 2009). R145W results in a non-conservative amino acid substitution of a positively charged Arginine with a non-polar Tryptophan, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. The R145 residue is highly conserved across species. Other mutations affecting the same residue (R145Q, R145G) and nearby residues (L144Q, L144P, S150C) have also been reported in association with cardiomyopathy, further supporting the functional importance of this residue and this region of the protein. In addition, the R145W mutation was not observed in approximately 6,000 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations.In summary, R145W in the TNNI3 gene is interpreted as a disease-causing mutation for HCM."}],"specifiedBy":"GeneValidityOverallAutosomalDominantOtherVariantEvidenceCriteria","strengthScore":7},{"id":"cggv:4a7e6901-d478-44c4-bd03-2c344029d4bb_ad_dn_el","type":"EvidenceLine","evidence":[{"id":"cggv:fac0fa51-b5ba-457e-a226-0df853b7b0a3_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:802fb804-4f61-49ba-b264-b9433544555d","type":"Proband","detectionMethod":"Parents genotype neg","sex":"UnknownEthnicity","variant":{"id":"cggv:fac0fa51-b5ba-457e-a226-0df853b7b0a3_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:9413bbba-36a2-401f-a190-c58fd9a5431d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000363.5(TNNI3):c.592C>G (p.Leu198Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA022019"}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/15698845"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/15698845","rdfs:label":"Family FC, II:1"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":1,"dc:description":"Variant absent from gnomAD"},{"id":"cggv:fac8c7d9-9395-444b-9ded-81d07e09d64d_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:887fa678-ed8f-46c4-94f7-f8668d8cb7f5","type":"Proband","detectionMethod":"PCR-DCP analysis: parents negative.","phenotypeFreeText":"sporadic HCM.","phenotypes":"obo:HP_0001714","previousTesting":true,"previousTestingDescription":"No mutations in 6 known HCM genes.","sex":"Male","variant":{"id":"cggv:fac8c7d9-9395-444b-9ded-81d07e09d64d_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:78ab8484-61a3-46ff-a296-4079bdbbee38","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000363.5(TNNI3):c.616A>C (p.Lys206Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA022072"}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/9241277"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/9241277","rdfs:label":"Family J907 Proband"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":1,"dc:description":"Variant absent from gnomAD; maternity and paternity not confirmed, no functional evidence"}],"specifiedBy":"GeneValidityOverallAutosomalDominantDeNovoVariantEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12}],"evidenceStrength":"Definitive","sequence":1741,"specifiedBy":"GeneValidityCriteria7","strengthScore":18,"subject":{"id":"cggv:ef9f6bf9-9a77-451a-9b2f-e1e72660bb4d","type":"GeneValidityProposition","disease":"obo:MONDO_0005045","gene":"hgnc:11947","modeOfInheritance":"obo:HP_0000006"},"version":"1.1","dc:description":"The TNNI3 gene has been associated with hypertrophic cardiomyopathy. TNNI3 was first associated with this disease in humans in 1997 (Kimura et al, PMID 9241277).  At least 60 unique variants, with varying levels of evidence to support their pathogenicity, have been reported in humans (reviewed in Mogensen et al, 2015, PMID 26440512). Variants in this gene segregated with disease in at least 6 families (Kimura et al, 1997, PMID 9241277; Rani et al, 2012, PMID 22876777; Choi et al, 2010, PMID 20641121; Mogensen et al, 2004, PMID 15607392). More evidence is available in the literature , but the maximum score for genetic evidence (12 pts) was reached. The mechanism for disease is likely dominant negative, as 91% of mutations reported are missense variants (Mogensen et al, 2015, PMID 26440512). The gene-disease association is supported by the function of the gene product, animal models, and in vitro assays. In summary, TNNI3 is definitively associated with hypertrophic cardiomyopathy. This has been repeatedly demonstrated in both research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen Hypertrophic Cardiomyopathy Gene Curation Committee, subgroup of the ClinGen Cardiovascular Working Group, on September 5, 2017.","dc:isVersionOf":{"id":"cggv:4a7e6901-d478-44c4-bd03-2c344029d4bb"},"@context":{"@vocab":"http://dataexchange.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"http://dataexchange.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"http://dataexchange.clinicalgenome.org/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"}}}